CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Varenicline Tartrate +1 moredrug
Likely dose
Varenicline Tartrate 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05541497
NCT05541497Phase 2Completed
CompareCT.gov

Varenicline for Treatment of E-cigarette Dependence

Yale University·interventional·Posted Sep 15, 2022·Updated Dec 2, 2024

In Brief

A Phase 2 clinical trial evaluating Varenicline Tartrate and Placebo for Smoking Cessation. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

Varenicline is used to treat tobacco use dependence. It helps reduce cravings for tobacco use and decreases the pleasurable effects of cigarettes and other tobacco products. Varenicline has been proven to reduce the desire to smoke cigarettes. This study aims to test whether it shows a similar benefit for individuals who vape and are interested in quitting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedSep 15, 2022
Enrollment StartNov 4, 2022
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.8 years ago

Interventions

Varenicline Tartratedrug

Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day

Placebodrug

Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day